BeiGene | A Study of BGB-A3055, Alone and in Combination With Tislelizumab in Participants With Selected Advanced or Metastatic Solid Tumors

⟵ Back to Search Results

BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors

Beigene Study ID

BGB-A317-A3055-101

ClinicalTrials.gov ID

NCT05935098

EudraCT Number

2023-505322-34-00

China Drug Trials ID

CTR20241681

Sex: All

Age: 18 Years / N/A

No Study Documents

Locations

Sex: All

Age: 18 Years / N/A

No Study Documents